StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.83+0.04 (+2.23%)

Close on Nov 17, 2026Market cap $108.68MP/E –Yield –

Foghorn Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Foghorn Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$72.76M. For fiscal 2025 it was -$86.39M. The highest annual figure on record is -$51.08M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$86.39M–
FY2024Dec 31, 2024-$102.68M–
FY2023Dec 31, 2023-$107.91M–
FY2022Dec 31, 2022-$117.14M–
FY2021Dec 31, 2021-$100.73M–
FY2020Dec 31, 2020-$68.53M–
FY2019Dec 31, 2019-$51.08M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.81M–
Q1 FY2026Mar 31, 2026-$21.57M–
Q4 FY2025Dec 31, 2025-$23.88M–
Q3 FY2025Sep 30, 2025-$18.50M–
Q2 FY2025Jun 30, 2025-$21.10M–
Q1 FY2025Mar 31, 2025-$22.91M–
Q4 FY2024Dec 31, 2024-$24.01M–
Q3 FY2024Sep 30, 2024-$23.85M–
Q2 FY2024Jun 30, 2024-$26.63M–
Q1 FY2024Mar 31, 2024-$28.19M–
Q4 FY2023Dec 31, 2023-$25.46M–
Q3 FY2023Sep 30, 2023-$17.08M–
Q2 FY2023Jun 30, 2023-$32.05M–
Q1 FY2023Mar 31, 2023-$33.32M–
Q4 FY2022Dec 31, 2022-$31.89M–
Q3 FY2022Sep 30, 2022-$28.26M–
Q2 FY2022Jun 30, 2022-$29.19M–
Q1 FY2022Mar 31, 2022-$27.80M–
Q4 FY2021Dec 31, 2021-$28.08M–
Q3 FY2021Sep 30, 2021-$26.26M–
Q2 FY2021Jun 30, 2021-$23.26M–
Q1 FY2021Mar 31, 2021-$23.13M–
Q4 FY2020Dec 31, 2020-$20.78M–
Q3 FY2020Sep 30, 2020-$18.49M–
Q2 FY2020Jun 30, 2020-$15.54M–
Q1 FY2020Mar 31, 2020-$13.72M–
Q4 FY2019Dec 31, 2019-$15.19M–
Q3 FY2019Sep 30, 2019-$13.10M–

More Foghorn Therapeutics figures

See a number that looks wrong?